Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9H8P0
UPID:
PORED_HUMAN
Alternative names:
3-oxo-5-alpha-steroid 4-dehydrogenase 3; Steroid 5-alpha-reductase 2-like; Steroid 5-alpha-reductase 3
Alternative UPACC:
Q9H8P0; Q4W5Q6
Background:
Polyprenol reductase, also known as 3-oxo-5-alpha-steroid 4-dehydrogenase 3, plays a crucial role in protein N-linked glycosylation. It is essential for converting polyprenol into dolichol, a key step in the synthesis of dolichol-linked monosaccharides and the oligosaccharide precursor used for N-glycosylation. Additionally, it functions as a polyprenol reductase, facilitating the reduction of polyprenols into dolichols in a NADP-dependent mechanism, and can convert testosterone into 5-alpha-dihydrotestosterone.
Therapeutic significance:
Polyprenol reductase is implicated in congenital disorder of glycosylation 1Q and Kahrizi syndrome, diseases characterized by a wide range of clinical features including defects in nervous system development and intellectual disability. Understanding the role of Polyprenol reductase could open doors to potential therapeutic strategies for these conditions.